Literature DB >> 27695935

Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.

Michael Paulzen1, Ekkehard Haen2, Benedikt Stegmann2, Stefan Unterecker3, Christoph Hiemke4, Gerhard Gründer5, Georgios Schoretsanitis5,6.   

Abstract

The purpose of this study was to disentangle an association between plasma concentrations of risperidone (RIS), its active metabolite 9-hydroxyrisperidone (9-OH-RIS) and the active moiety, AM (RIS + 9-OH-RIS), and clinical response in a naturalistic sample. Plasma concentrations of RIS, 9-OH-RIS and AM in patients out of a therapeutic drug monitoring (TDM) database were compared between responders (n = 64) and non-responders (n = 526) using the Clinical Global Impressions (CGI) Scale. Daily dosage of risperidone did not differ between responders and non-responders. Differences for active moiety plasma levels between the two groups did not reach statistical significance. However, responders showed lower plasma concentrations of the parent compound RIS as well as lower metabolic ratios RIS/9-OH-RIS than non-responders (p = 0.017 and p = 0.034). These differences did not remain after controlling for age and baseline symptoms. Furthermore, the cohort was split into two subgroups based on the daily dosage: patients under high (≥6 mg/day) (R H, n = 187) and patients under lower dosages (<6 mg) (R L, n = 403) of risperidone. Differences between responders and non-responders after controlling for demographic and clinical characteristics remained only for plasma concentrations of active moiety in the lower-dose medicated groups; non-responders showed higher active moiety plasma concentrations than responders. Understanding the mechanisms involved and factors associated with the clinical response in patients medicated with antipsychotics is of great interest. Our data imply that clinical response to an antipsychotic treatment cannot be attributed to a single pharmacokinetic pattern. It seems to be rather a complex patchwork of influencing factors such as demographic and clinical characteristics as well as the metabolizer status as surrogate of CYP activity. It seems that the ratio between RIS and 9-OH-RIS may play a crucial role in mediating the clinical effect.

Entities:  

Keywords:  CGI; Plasma concentration; Risperidone; Therapeutic drug monitoring; Treatment response

Mesh:

Substances:

Year:  2016        PMID: 27695935     DOI: 10.1007/s00406-016-0736-z

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  39 in total

Review 1.  Diagnosis and definition of treatment-resistant depression.

Authors:  Maurizio Fava
Journal:  Biol Psychiatry       Date:  2003-04-15       Impact factor: 13.382

Review 2.  Treatment-resistant schizophrenia.

Authors:  Helio Elkis
Journal:  Psychiatr Clin North Am       Date:  2007-09

3.  Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

Authors:  Shingo Kakihara; Reiji Yoshimura; Koji Shinkai; Chima Matsumoto; Makiko Goto; Kyoko Kaji; Yasuhisa Yamada; Nobuhisa Ueda; Osamu Ohmori; Jun Nakamura
Journal:  Int Clin Psychopharmacol       Date:  2005-03       Impact factor: 1.659

4.  Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.

Authors:  M C Mauri; V Laini; L Boscati; R Rudelli; V Salvi; R Orlandi; P Papa
Journal:  Eur Psychiatry       Date:  2001-02       Impact factor: 5.361

5.  Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.

Authors:  Michael Paulzen; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Sarah E Lammertz; Georgios Schoretsanitis
Journal:  Psychoneuroendocrinology       Date:  2016-07-18       Impact factor: 4.905

6.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; Serge Beaulieu; Martin Alda; Claire O'Donovan; Glenda Macqueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Roumen Milev; David J Bond; Benicio N Frey; Benjamin I Goldstein; Beny Lafer; Boris Birmaher; Kyooseob Ha; Willem A Nolen; Michael Berk
Journal:  Bipolar Disord       Date:  2012-12-12       Impact factor: 6.744

7.  Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy.

Authors:  Zhiyun Wei; Lei Wang; Tao Yu; Yang Wang; Liya Sun; Ti Wang; Ran Huo; Yang Li; Xi Wu; Shengying Qin; Yifeng Xu; Guoyin Feng; Lin He; Qinghe Xing
Journal:  J Clin Psychopharmacol       Date:  2013-04       Impact factor: 3.153

8.  Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.

Authors:  Ilja Spellmann; Dan Rujescu; Richard Musil; Sebastian Meyerwas; Ina Giegling; Just Genius; Peter Zill; Sandra Dehning; Anja Cerovecki; Florian Seemüller; Rebecca Schennach; Annette M Hartmann; Martin Schäfer; Norbert Müller; Hans-Jürgen Möller; Michael Riedel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-02-25       Impact factor: 5.067

9.  Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.

Authors:  Po See Chen; Yen Kuang Yang; Sheng-Fang Su; Yi-Cheng Liao; Jung-Wei Chang; Tzung Lieh Yeh
Journal:  Psychiatry Clin Neurosci       Date:  2004-04       Impact factor: 5.188

10.  Pharmacokinetic patterns of risperidone-associated adverse drug reactions.

Authors:  Georgios Schoretsanitis; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Koen R J Schruers; Sebastian Walther; Sarah E Lammertz; Ekkehard Haen; Michael Paulzen
Journal:  Eur J Clin Pharmacol       Date:  2016-07-04       Impact factor: 2.953

View more
  2 in total

Review 1.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

2.  Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.

Authors:  Michael Paulzen; Ekkehard Haen; Christoph Hiemke; Benedikt Stegmann; Sarah E Lammertz; Gerhard Gründer; Georgios Schoretsanitis
Journal:  Br J Clin Pharmacol       Date:  2017-03-02       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.